There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
This situation is taking its toll across the industry as reflected in the recently reported results of Medtronic's peers, Boston Scientific ( BSX ) and St Jude Medical ( STJ ). Moreover, the Spinal segment is also witnessing several headwinds such as...
In our rather terse (due to firm involvement) post on Monday concerning Merck & Co. v. Ratliff, ___ S.W.3d ___, 2012 WL 413522 (Ky. App. Feb. 10, 2012) – beating both BNA and 360 by two days, BTW – we mentioned the “interesting” aspects of that case. ...
This undated photo provided by Boston Scientific Corp. , shows Michael Mahoney who will appointed president of Boston Scientific Corp. , Oct. 17, 2011. Boston Scientific Corp.'s choice of Johnson & Johnson executive Michael Mahoney to become its next... View Photo »
The Epic Stent is a novel stent platform designed to offer both acute and clinical advantages over older-generation stent systems. Upon approval, the Epic Stent along with the market-leading Express® LD balloon-expandable iliac stent, would enable Boston Scientific to offer a complete line of advanced i...
The medical-device company's stock rose 1.36% Thursday to close at $5.97. The slow-moving shares rallied from a long-term low of $5 to $6 between mid-December and mid-January and have been consolidating since then. OptionMonster's tracking systems show...
Boston Scientific [ BSX 5.97 +0.08 (+1.36%) ] rose 1.36 percent yesterday to close at $5.97. Shares of the slow-moving medical-device company rallied from a long-term low of $5 to $6 between mid-December and mid-January and have been consolidating...
It was a timely reminder about the dangers of stifling private-sector medical innovation. No one listened. Stents don't grow on trees. They were not created, developed, marketed or sold by government bureaucrats and lawmakers. One of the nation's top...
We estimate Quad-Pole technology from Medtronic Inc. (MDT) and Boston Scientific Corp. (BSX) are at least one to two years behind Quartet, so St. Jude has a meaningful lead
It was a timely reminder about the dangers of stifling private-sector medical innovation. No one listened. Stents don't grow on trees. They were not created, developed, marketed or sold by government bureaucrats and lawmakers. One of the nation's top...
US medical equipment and supplies manufacturing industry includes about 11,000 companies with combined annual revenue of about $85 billion. Major companies include Baxter International, Boston Scientific, Johnson & Johnson, and Medtronic. The industry...
The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery,... Full Article
The Epic Stent is a novel stent platform designed to offer both acute and clinical advantages over older-generation stent systems. Upon approval, the Epic Stent along with the market-leading Express® LD balloon-expandable iliac stent, would enable Boston Scientific to offer a complete line of advanced i...
We estimate Quad-Pole technology from Medtronic Inc. (MDT) and Boston Scientific Corp. (BSX) are at least one to two years behind Quartet, so St. Jude has a meaningful lead
This should be a strong positive for St Jude’s CRT-D business, and when combined with the accelerating replacement cycle should allow the company to continue to take share from competitors Boston Scientific and Medtronic – the European experience has been positive.
This approval marks an important milestone for Boston Scientific — the beginning of a transition to higher margins on our everolimus stent offering in the U.S. as we shift from the PROMUS Stent to the internally manufactured PROMUS Element Plus Stent System
While we continue to watch this issue closely, we think that the Promus Element approval may indicate that FDA is not overly concerned about longitudinal compression ... We continue to believe that Boston Scientific is in the early stages of a turnaround in terms of both revenue growth and margins. The ...
FDA is actively working with (drug-eluting stent) manufacturers, including Boston Scientific, to better understand longitudinal stent deformation with respect to its causes, predisposing underlying anatomic conditions, operator techniques that can reduce the likelihood of its occurrence, and treatment s...
